Apellis Pharmaceuticals (APLS) - Stock & Dividends

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is a biopharmaceutical company that focuses on developing and commercializing therapeutic compounds by targeting the complement system for the treatment of autoimmune and inflammatory conditions. One of its key products, EMPAVELI, is used to address various diseases such as paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, and amyotrophic lateral sclerosis. Another significant offering is SYFOVRE, designed for treating geographic atrophy (GA).

Moreover, the company's pipeline includes APL-2006, a dual-action inhibitor targeting C3 and VEGF for wet age-related macular degeneration and GA, as well as APL-1030, a C3 inhibitor for neurodegenerative disorders. Apellis Pharmaceuticals is also working on combining EMPAVELI with small interfering RNA to decrease liver-produced C3 proteins.

Established in 2009 and headquartered in Waltham, Massachusetts, Apellis Pharmaceuticals Inc collaborates with Swedish Orphan Biovitrum AB (publ) for the development and commercialization of pegcetacoplan. Furthermore, the company has a partnership with Beam Therapeutics Inc to utilize base editing technology in exploring innovative treatments for complement-related diseases.

For more information, you can visit their website at https://www.apellis.com.